Neurology Study Pinpoints Potential New Drug Target for Protection against Certain Neurodegenerative Diseases
March 20, 2015
Penn Medicine researchers have discovered that hypermethylation - the epigenetic ability to turn down or turn off a bad gene implicated in 10 to 30 percent of patients with Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Degeneration (FTD) - serves as a protective barrier inhibiting the development of these diseases. Their work, published this month in Neurology, may suggest a neuroprotective target for drug discovery efforts.
Read the Department of Communications news release.
Listen to an American Academy of Neurology podcast on the paper.